Probenecid: Novel use as a non-injurious positive inotrope acting via cardiac TRPV2 stimulation

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 1, 2012, Pages 134-144

  Koch, Sheryl E ^a   Gao, Xiaoqian ^a   Haar, Lauren ^b   Jiang, Min ^a   Lasko, Valerie M ^b   Robbins, Nathan ^a   Cai, Wenfeng ^a   Brokamp, Cole ^a   Varma, Priyanka ^a   Tranter, Michael ^a   Liu, Yong ^a   Ren, Xiaoping ^a   Lorenz, John N ^b   Wang, Hong Sheng ^a   Jones, W Keith ^a   Rubinstein, Jack ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Calcium handling; Echocardiography; Inotropic agent; Probenecid; TRPV2

Indexed keywords

PROBENECID; VANILLOID RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; EX VIVO STUDY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; INOTROPISM; ISOLATED HEART; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM; CALCIUM CHANNELS; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HEART; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PROBENECID; RNA, MESSENGER; TRPV CATION CHANNELS;

MUS;

EID: 84861963118     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.04.011     Document Type: Article

References (58)

1. Beyer R.H., Wiebelhaus V.D., Russe H.F., Peck H.M., McKinney S.E. Benemid: an anticatabolite; its pharmacological properties. Fed Proc 1950, 9:258.
2. Beyer K.H., Russo H.F., Tillson E.K., Miller A.K., Verwey W.F., Gass S.R. 'Benemid', p-(di-n-propylsulfamyl)-benzoic acid; its renal affinity and its elimination. Am J Physiol 1951, 166(3):625-640.
3. Boger W.P., Beatty J.O., Pitts F., Flippin H.F. The influence of a new benzoic acid derivative on the metabolism of para-aminosalicylic acid (PAS) and penicillin. Ann Intern Med 1950, 33(1):18-31.
4. Boger W.P., Pitts F.W., Gallagher M.E. Benemid and Carinamide: Comparison of effect on Para-amino-salicylic acid (PAS) Plasma Concentrations. J Lab Clin Med 1950, 36:276-282.
5. Boger W.P., Strickland S.C. Probenecid (Benemid): its uses and side effects in 2502 patients. AMA Arch Intern Med 1955, 95:83-92.
6. Burnell J.M., Kirby W.M.M. Effectiveness of a new compound, Benemid, in elevating serum penicillin concentrations. J Clin Invest 1951, 30:697-700.
7. Meads M., Knight V.H., Izlar H.R. The enhancement of serum penicillin in man by Benemid. South Med J 1951, 44(4):297-302.
8. Butler D. Wartime tactics doubles power of scarce bird-flu drug. Nature 2005, 438:6.
9. Korf J., van Praag H.M. The intravenous probenecid test: a possible aid in evaluation of the serotonin hypothesis on the pathogenesis of depressions. Psychopharmacologia 1970, 18(1):129-132.
10. Kenwright S., Levi A.J. Impairment of hepatic uptake of rifamycin antibiotics by probenecid, and its therapeutic implications. Lancet 1973, 302(7843):1401-1405.
11. Forbes M., Becker B. The transport of organic anions by the rabbit eye. II. In vivo transport of iodopyracet (Diodrast). Am J Ophthalmol 1960, 50:867-875.
12. Roch-Ramel F., Guisan B. Renal transport of urate in humans. News Physiol Sci 1999, 14:80-84.
13. Bronsky D., Dubin A., Kusher D.S. Diuretic action of Benemid: its effects upon the urinary excretion of sodium, chloride, potassium, and water in edematous subjects. Am J Med 1954, 18:259-266.
14. Kushner D., Dubin A., Bronsky D. Effect of Benemid on excretion of water, sodium and chloride in congestive heart failure. Fed Proc 1954, 13:435.
15. Reynolds E.S., Schlant R.C., Gonick H.C., Dammin G.J. Fatal massive necrosis of the liver as a manifestation of hypersensitivity to Probenecid. N Engl J Med 1957, 256:592-596.
16. Rider T.G., Jordan K.M. The modern management of gout. Rheumatology 2010, 49:830.
17. Bang S., Kim K.Y., Too S., Lee S.H., Hwang S.W. Transient receptor potential V2 expressed in sensory neurons is activated by Probenecid. Neurosci Lett 2007, 435:120-125.
18. Inoue R., Jensen L.J., Shi J., Morita H., Nishida M., Honda A., et al. Transient receptor potential channels in cardiovascular function and disease. Circ Res 2006, 99:119-131.
19. Wu X., Eder P., Chang B., Molkentin J.D. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc Natl Acad Sci U S A 2010, 107:7000-7005.
20. 2+-permeable growth factor-regulated channel. J Cell Biol 2003, 161:957-967.
21. Huang W., Rubinstein J., Prieto A.R., Thang L.V., Wang D.H. Transient receptor potential vanilloid gene deletion exacerbates inflammation and atypical cardiac remodeling after myocardial infarction. Hypertension 2009, 53(2):243-250.
22. Ueda K., Tsuji F., Hirata T., Takaoka M., Matsumura Y. Preventive effect of TRPV1 agonists capsaicin and resiniferatoxin on ischemia/reperfusion-induced renal injury in rats. J Cardiovasc Pharmacol 2008, 51:513-520.
23. Wang L., Wang D.H. TRPV1 gene knockout impairs postischemic recovery in isolated perfused heart in mice. Circulation 2005, 112:3617-3623.
24. Park U., Vastani N., Guan Y., Raja S.N., Koltzenburg M., Caterina M.J. TRP Vanilloid 2 knockout mice are susceptible to perinatal lethality but display normal thermal and mechanical nociception. J Neurosci 2011, 31(32):11425-11436.
25. Ren X., Wang Y., Jones W.K. TNF-α is required for late ischemic preconditioning but not for remote preconditioning of trauma. J Surg Res 2004, 121:120-129.
26. Mundiña-Weilenmann C., Vittone L., Ortale M., de Cingolani G.C., Mattiazzi A. Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart. J Biol Chem 1996, 271:33561-33567.
27. Said M., Vittone L., Mundiña-Weilenmann C., Ferrero P., Kranias E.G., Mattiazzi A. Role of dual-site phospholamban phosphorylation in the stunned heart from phospholamban site-specific mutants. Am J Physiol Heart Circ Physiol 2003, 285:H1198-H1205.
28. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
29. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45.
30. Kadambi V.J., Ponniah S., Harrer J.M., Hoit B.D., Dorn G.W., Walsh R.A., et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 1996, 97:533-539.
31. Bouvy M.L., Heerdink E.R., De Bruin M.L., Herings R.M.C., Leufkens H.G.M., Hoes A.W. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med 2000, 160:2477-2480.
32. Williamson K.M., Thrasher K.A., Fulton K.B., LaPointe N.M.A., Dunham G.D., Cooper A.A., et al. Digoxin toxicity: an evaluation in current clinical practice. Arch Intern Med 1998, 158:2444-2449.
33. Vamos E., Pardutz A., Fejes A., Tajti J., Toldi J., Vecsei L. Modulatory effects of probenecid on the nitroglycerin-induced changes in the rat caudal tribeminal nucleus. Eur J Pharmacol 2009, 621:33-37.
34. Vecsei L., Miller J., MacGarvey U., Beal M.F. Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain. Brain Res Bull 1992, 28:233-238.
35. Neff N.H., Tozer T.N., Brodie B.B. Application of steady-state kinetics to studies of the transfer of 5-hydroxyindolacetic acid and from brain to plasma. J Pharmacol Exp Ther 1967, 158:214-218.
36. Guldberg H.C., Ashcroft G.W., Crawford T.B.B. Concentration of 5-hydroxyindolyacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with Probenecid. Life Sci 1966, 5:1571-1575.
37. Lake C.R., Wood J.H., Ziegler M.G., Ebert M.H., Kopin I.J. Probenecid-induced norepinephrine elevations in plasma and CSF. Arch Gen Psychiatry 1978, 35:237-240.
38. Gordon E.K., Markey S.P., Sherman R.L., Kopin I.J. Conjugated 3,4 dihydroxyphenyl acetic acid (DOPAC) in human and monkey cerebrospinal fluid and rat brain and the effects of Probenecid. Life Sci 1976, 18:1285-1292.
39. Tamarkin N.R., Goodwin F.K., Axelrod J. Rapid elevation of biogenic amine metabolites in human CSF following probenecid. Life Sci 1970, 9:1397-1408.
40. Maroko P.R., Kjekshus J.K., Sobel B.E., Watanabe T., Covell J.W., Ross J., et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971, 43:67-82.
41. Davidson S., Maroko P.R., Braunwald E. Effects of isoproterenol on contractile function of the ischemic and anoxic heart. Am J Physiol 1974, 227(2):439-443.
42. Shizukuda Y., Buttrick P.M., Geenen D.L., Borczuk A.C., Kitsis R.N., Sonnenblick E.H. Beta-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am J Physiol Heart Circ Physiol 1998, 275(3 Pt 2):H961-H968.
43. Simspon P. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J Clin Invest 1983, 72(2):732-738.
44. Bangalore S., Messerli F.H., Kostis J.B., Pepine C.J. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007, 50:563-572.
45. Feldman D., Elton T.S., Menachemi D.M., Wexler R.K. Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine. Vasc Health Risk Manag 2010, 6:387-397.
46. Shibasaki K., Murayama N., Ono K., Ishizaki Y., Tominaga M. TRPV2 enhances axon outgrowth through its activation by membrane stretch in developing sensory and motor neurons. J Neurosci 2010, 30:4601-4612.
47. Vriens J., Appendino G., Nilius B. Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 2009, 75:1262-1279.
48. 2+ uptake in apoptosis. Cell Calcium 2006, 40:553-560.
49. 2+ release channel in visceral muscle. Proc Natl Acad Sci U S A 1994, 91:3294-3298.
50. Stokes A.J., Wakano C., del Carmen K.A., Koblan-Huberson M., Turner H. Formation of a physiological complex between TRPV2 and RGA protein promotes cell surface expression of TRPV2. J Cell Biochem 2005, 94(4):669-683.
51. Muraki K., Iwata Y., Katanosaka Y., Ito T., Ohya S., Shigekawa M., et al. TRPV2 is a component of osmotically sensitive cation channels in murine aortic myocytes. Circ Res 2003, 93:829-838.
52. Boels K., Glassmeier G., Herrman D., Riedel B., Hampe W., Kojima I., et al. The neuropeptide head activator induces activation and translocation of the growth-factor-regulated Ca(2+)-permeable channel GRC. J Cell Sci 2001, 114(Pt. 20):3599-3606.
53. Nagasawa M., Nakagawa Y., Tanaka S., Kojima T. Chemotactic peptide fMetLeuPhe induces translocation of the TRPV2 channel in macrophages. J Cell Physiol 2007, 210:692-702.
54. Hisanaga E., Nagasawa M., Ueki K., Kulkarni R.N., Mori M., Kojima I. Regulation of calcium-permeable TRPV2 channel by insulin in pancreatic β-cells. Diabetes 2009, 58:174-184.
55. Kanzaki M., Zhang Y.-Q., Mashima H., Li L., Shibata H., Kojima I. Translocation of a calcium-permeable cation channel induced by insulin-like growth factor-I. Nat Cell Biol 1999, 1(3):165-170.
56. Selen A., Amidon G.L., Welling P.G. Pharmacokinetics of probenecid following oral doses to human volunteers. J Pharm Sci 1982, 71(11):1238-1242.
57. Gutman A.B., Yu T.F. Benemid (p-di-n-propylsulfamyl)-benzoic acid) as uricosuric agent in chronic gouty arthritis. Trans Assoc Am Physicians 1951, 64:279-288.
58. Smith D.E., Gee W.L., Brater D.C., Lin E.T., Benet L.Z. Preliminary evaluation of furosemide-probenecid interaction in humans. J Pharmacol Sci 1980, 69(5):571-575.